Company Overview - Nyxoah is a medical technology company focused on developing and commercializing innovative solutions for treating Obstructive Sleep Apnea (OSA) [3] - The company's lead product is the Genio® system, which is a patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy for OSA [3] Recent Developments - Nyxoah will participate in the Jefferies Global Healthcare Conference on June 5-6, 2024, in New York [1] - CEO Olivier Taelman will deliver a corporate presentation on June 5, 2024, at 7:30 am ET, with a webcast available on the company's Investor Relations website [2] - The company will also hold one-on-one meetings with institutional investors during the conference [2] Product Milestones - The Genio® system received its European CE Mark in 2019 following the successful completion of the BLAST OSA study [4] - Nyxoah completed IPOs on Euronext Brussels in September 2020 and NASDAQ in July 2021 [4] - The company received CE mark approval for expanding therapeutic indications to Complete Concentric Collapse (CCC) patients after positive outcomes from the BETTER SLEEP study [4] - Currently, Nyxoah is conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval [4]

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), June 3, 2024, 10.05pm CET / 4.05pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received four transparency notifications as detailed below. FMR LLC On May 30, 2024, Nyxoah received a transparency notification from FMR LLC following the crossing above the 3% threshold on May 28, 2024. As of ...

Core Points - Nyxoah SA received multiple transparency notifications regarding significant changes in shareholdings from various entities, indicating increased interest and investment in the company [1][2][8][13][15]. Group 1: FMR LLC Notification - On May 30, 2024, FMR LLC reported crossing the 3% threshold, holding 1,698,402 voting rights, which is 4.99% of the total voting rights as of May 28, 2024 [2][5]. - The breakdown of voting rights includes 1,613,888 shares and 84,514 equivalent financial instruments [2][4]. - The notification was triggered by the acquisition of voting securities [2][6]. Group 2: BlackRock Notification - BlackRock, Inc. also crossed the 3% threshold on May 28, 2024, holding 1,116,429 voting rights, representing 3.28% of the total voting rights [8][10]. - This holding consists of 1,097,929 shares and 18,500 equivalent financial instruments [8][10]. - The notification was due to the acquisition of voting securities [9][12]. Group 3: Together Partnership Notification - Together Partnership reported a passive crossing below the 10% threshold, holding 2,940,258 shares, which is 8.63% of the total voting rights as of May 28, 2024 [13][14]. - The notification indicates a reduction in their holdings [13][15]. Group 4: Gilde Healthcare Notification - Gilde Healthcare Holding BV and Gilde Healthcare III Management BV reported a passive crossing below the 10% threshold, holding 2,936,890 shares, representing 8.62% of the total voting rights as of May 28, 2024 [15][17]. - This notification also reflects a decrease in their holdings [15][19].

INSIDE INFORMATION REGULATED INFORMATION Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares Mont-Saint-Guibert, Belgium – May 31, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/ Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the closing of its previously announced underwritten public offering in t ...

INSIDE INFORMATION REGULATED INFORMATION Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares Mont-Saint-Guibert, Belgium – May 31, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/ Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the closing of its previously announced underwritten public offering in t ...

Information on the Total Number of Voting Rights and Shares Mont-Saint-Guibert (Belgium), May 28, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. * * REGULATED INFORMATION Attachment * Share capital: EUR 5,851,253.43 Total number of securities carrying voting rights: 34,060,390 (all ordinary shares) Total number o ...

Nyxoah intends to use the net proceeds from the proposed offering (i) for pre-commercialization and commercialization activities in the United States; (ii) to continue gathering clinical data and to support physician initiated clinical research projects related to OSA patient treatments; (iii) to further finance research and development activities related to the next generation of the Genio system and to continue to build a pipeline of new technologies and explore potential collaboration opportunities in th ...

About Nyxoah REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Pricing of Offering Mont-Saint-Guibert, Belgium – May 23, 2024, 3:50 pm CET / 9:50 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced today the pricing of an underwritten public offering in the United States, which includes shares sold in a private offering to ...

Nyxoah Announces Reduction of the Maximum Amount Available Under its At-the-Market Equity Offering Program Mont-Saint-Guibert, Belgium – May 22, 2024, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced today that it has reduced the maximum amount of 6,000,000 ordinary shares available for issuance under its "at- ...

REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Reduction of the Maximum Amount Available Under its At-the-Market Equity Offering Program Mont-Saint-Guibert, Belgium – May 22, 2024, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced today that it has reduced the maximum amount of 6,000,000 ordinary sha ...